University of Limerick
Barreto_2024_Enzymatic.pdf (3.25 MB)

Enzymatic metabolic switches of astrocyte response to lipotoxicity as potential therapeutic targets for nervous system diseases

Download (3.25 MB)
journal contribution
posted on 2024-06-04, 11:07 authored by Andrea Angarita-Rodríguez, J. Manuel Matiz-González, Andrés Pinzón, Andrés Felipe Aristizabal, David Ramírez, GEORGE BARRETOGEORGE BARRETO, Janneth González

Abstract: Astrocytes play a pivotal role in maintaining brain homeostasis. Recent research has high-lighted the significance of palmitic acid (PA) in triggering pro-inflammatory pathways contributing to neurotoxicity. Furthermore, Genomic-scale metabolic models and control theory have revealed that metabolic switches (MSs) are metabolic pathway regulators by potentially exacerbating neurotoxicity, thereby offering promising therapeutic targets. Herein, we characterized these enzymatic MSs in silico as potential therapeutic targets, employing protein–protein and drug–protein interaction networks alongside structural characterization techniques. Our findings indicate that five MSs (P00558, P04406, Q08426, P09110, and O76062) were functionally linked to nervous system drug targets and may be indirectly regulated by specific neurological drugs, some of which exhibit polypharmacological potential (e.g., Trifluperidol, Trifluoperazine, Disulfiram, and Haloperidol). Furthermore, four MSs (P00558, P04406, Q08426, and P09110) feature ligand-binding or allosteric cavities with druggable potential. Our results advocate for a focused exploration of P00558 (phosphoglycerate kinase 1), P04406 (glyceraldehyde-3-phosphate dehydrogenase), Q08426 (peroxisomal bifunctional enzyme, enoyl-CoA hydratase, and 3-hydroxyacyl CoA dehydrogenase), P09110 (peroxisomal 3-ketoacyl-CoA thiolase), and O76062 (Delta(14)-sterol reductase) as promising targets for the development or repurposing of pharmacological compounds, which could have the potential to modulate lipotoxic-altered metabolic pathways, offering new avenues for the treatment of related human diseases such as neurological diseases.



Pharmaceuticals 17(5), 648



Other Funding information

Pontificia Universidad Javeriana, Bogotá, Colombia, associated with the project BPIN2020000100357 financed by the Sistema General de Regalías SGR to J.G.

Also affiliated with

  • Health Research Institute (HRI)

Department or School

  • Biological Sciences

Usage metrics

    University of Limerick


    Ref. manager